| [1] 邢宝鹏,纪 莉. 冠状动脉粥样硬化性心脏病相关危险因素及临床特点分析[D].长春:吉林大学,2012.[2] 黄 燕. 炎性因子在动脉粥样硬化形成中的作用[D]. 天津:天津医科大学, 2012.[3] Shirai T, Hilhorst M, Harrison DG,et al. Macrophages in vascular inflammation-From atherosclerosis to vasculitis[J]. Autoimmunity, 2015,48(3): 139-151.[4] Eames HL, Saliba DG, Krausgruber T,et al. KAP1/TRIM28: an inhibitor of IRF5 function in inflammatory macrophages[J]. Immunobiology, 2012,217(12):1315-1324.[5] Kim K, Cho SK, Han TU,et al. A redundant epistatic interaction between IRF5 and STAT4 of the type Ⅰ interferon pathway in susceptibility to lupus and rheumatoid arthritis[J]. Lupus,2013,22(13):1336-1340.[6] Maalej A, Hamad MB, Rebai A, et al. Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population[J]. Scand J Rheumatol, 2008,37(6):414-418.[7] Gestermann N, Koutero M, Belkhir R, et al. Methylation profile of the promoter region of IRF5 in primary Sjogren's syndrome[J]. Eur Cytokine Netw, 2012,23(4):166-172.[8] Krausgruber T, Saliba D, Ryzhakov G, et al. IRF5 is required for late-phase TNF secretion by human dendritic cells[J]. Blood,2010,115(22):4421-4430.[9] Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses[J]. Nat Immunol, 2011,12(3):231-238.[10] Mantovani A, Sozzani S, Locati M, et al.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes[J]. Trends Immunol, 2002,23(11),549-555.[11] Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways[J]. Circ Res, 2011, 108(8) :985-995.[12] Malarstig A, Sigurdsson S, Eriksson P, et al. Variants of the interferon regulatory factor 5 gene regulate expression of IRF5 mRNA in atherosclerotic tissue but are not associated with myocardial infarction[J]. Arterioscler Thromb Vasc Biol, 2008,28(5):975-982.[13] Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses the type I interferon response,a family of potentantiviral immunoregulators,in macrophages challenged with lipopolysaccharide[J].Circulation,2010,122(19):1919-1927.[14] Takaoka A,Yanai H,Kondo S,et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors[J]. Nature,2005,434(7030): 243-249.[15] Courties G, Heidt T, Sebas M, et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing[J]. J Am Coll Cardiol, 2014,63(15): 1556-1566.[16] Xu WD, Pan HF, Xu Y,et al. Interferon regulatory factor 5 and autoimmune lumps[J]. Expert Rev Mol Med, 2013,15:e6. |
